Press Information
Please use this monthly updated Media section to access more tools, information and photos available for the press and to be downloaded, in both German and English.
Bitte verwenden Sie diesen monatlich aktualisierten Medienbereich, um auf weitere Tools, Informationen und Fotos zuzugreifen, die für die Presse verfügbar und für Download in deutscher und englischer Sprache verfügbar sind.
Press publication June 2022:
Laboratorios Gebro Pharma and BIT Pharma sign an agreement for the future marketing of NicaPlant® in Spain.
Here below the link to their press release.
Press publications April 2021:
It seems there may be more roles to play for Nicardipine, than acting as a vasodilator.
Read about how Nicardipine sensitizes temozolomide by inhibiting autophagy and promoting cell apoptosis in glioma stem cells. The article has been recently published in Aging 13(5):6820-6831. doi: 10.18632/aging.202539.
https://pubmed.ncbi.nlm.nih.gov/33621205
Press publications March 2021:
BIT Pharma announces that the independent Data Safety Monitoring Board (DSMB) led by Prof Dr Gerrit Schubert has reviewed, as planned, the analysed data of the initial 50 % patients in the on-going Phase IIb trial of the lead product NicaPlant® in aneurysmal subarachnoid haemorrhage patients and has concluded that it is safe and appropriate to continue patient recruitment according to the study protocol.
The DSMB’s decision marks an important milestone in this trial as it confirms the advancement of NicaPlant® and the collection and analysis of valuable efficacy readouts that are expected later this year.
Press publications November 2020:
BIT Pharma is proud to share the data generated by Professor Hidetoshi Kasuya on the 12-year single critical care center experience of nicardipine prolonged-release implants in patients with subarachnoid hemorrhage at the Tokyo Women’s Medical University.
The data confirmed that the treatment with NPRIs (nicardipine prolonged release implants) significantly reduced the occurrence of cerebral vasospasm and delayed cerebral infraction without any side effects.
Press publications July 2020:
BIT Pharma is again in the local news. Read about us and our lead product NicaPlant on pages 46-49 of the current number (06/2020, in German) of Spirit of Styria
https://lnkd.in/ebeSgRy
Link to the article on BIT Pharma on Fazit number of July/2020 (Page 55, in German)
https://www.fazitmagazin.at/2020/07/
Link to the article on BIT Pharma on Human Technology Styria publication botenstoff 02/2020 (In German)
Press release June 2020:
bitpharma_presseinfo_2020_06_24
Press release May 2020
Link to the APA website:
For additional information:
bitpharma_presseinfo_2020_05_12 bitpharma_presseinfo_2020_05_12
Printing of all images with copyright information free of charge.
Abdruck aller Bilder mit Copyrightangabe honorarfrei.
Dr. Jörg Breitenbach, einer der Gründer und Geschäftsführer von BIT Pharma | © BIT Pharma
Prof. Dr. Peter Vajkoczy, Direktor der Klinik für Neurochirurgie mit Arbeitsbereich Pädiatrische Neurochirurgie (CVK), Charité – Universitätsmedizin Berlin | © Charité – Universitätsmedizin Berlin
Prof. Dr. Claudius Thomé, Direktor der Universitätsklinik für Neurochirurgie, Innsbruck | © Universitätsklinik für Neurochirurgie, Innsbruck
Schema des Einsatzes von NicaPlant® | © BIT Pharma
Operation am Gehirn and der Charité in Berlin | © Charité – Universitätsmedizin Berlin
BIT Pharma logo | © BIT Pharma
